Onkológia 3/2019
Non-metastatic castration-resistant prostate cancer
This review deals with current treatment options for men with high-risk non-metastatic castration-resistant prostate cancer characte- rized by increased plasma PSA levels during continuous androgen deprivation therapy (bilateral orchiectomy, LHRH agonist or LHRH antagonist), castration levels of plasma testosterone, PSA doubling time 10 months or shorter, and absent distant metastases on ima- ging examinations. Recently, the results of studies with new non-steroidal antiandrogens with a comparable adverse event profile were published. All of them proved to show significant metastasis-free survival improvement over more than twenty months compared to placebo. Currently, apalutamide, enzalutamide, and darolutamide are considered to be the new standard of treatment.
Keywords: prostate cancer, castration resitance, apalutamide, enzalutamide, darolutamide












